期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

92例多发性骨髓瘤合并肾功能不全患者的临床分析 被引量：2

原文传递
导出
摘要 多发性骨髓瘤（MM）是一种恶性浆细胞疾病，浆细胞单克隆增殖产生的免疫球蛋白及轻链引起的肾功能损害在临床上主要表现为肾功能不全，预后较不伴有肾功能不全的骨髓瘤患者差，是造成骨髓瘤患者死亡的最常见原因之一。我们回顾性分析了92例MM合并肾功能不全的患者资料，旨在分析其临床特征及预后。
作者 闫岩 侯健 傅卫军 袁振刚 张春阳
机构地区 第二军医大学长征医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2010年第9期629-631,共3页 Chinese Journal of Hematology
关键词 多发性骨髓瘤 肾功能不全 患者资料 临床分析 恶性浆细胞疾病 肾功能损害 主要表现 克隆增殖
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1张之南.血液病诊断及疗效标准.3版.北京:科学出版社,2008.106-113.
  • 2Chan DT,Craig K,Donovan K,et al.Myeloma renal disease:presentation and outcome.Nephron Clin Pract,2006,104:126-131.
  • 3Montseny JJ,Kleinknecht D,Meyrier A,et al.Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies.Nephrol Dial Transplant,1998,13:1438-1445.
  • 4Bladé J,Rosinol L.Renal,hematologic and infectious complications in multiple myeloma.Best Pract Res Clin Haematol,2005,18:635-652.
  • 5Montagut C,Bosch F,Villela L,et al.Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.Leuk Lymphoma,2004,45:1711-1712.
  • 6Blade J,Fernandez-Llama P,Bosch F,et al.Renal failure in multiple myeloma:presenting features and predictors of outcome in 94 patients from a single institution.Arch Intern Med,1998,158:1189-1193.
  • 7Knudsen LM,Hjorth M,Hippe E,et al.Renal failure in myeloma reversibility and impact on the prognosis.The Nordic Myeloma Study Group.Eur J Haematol,2000,65:175-181.
  • 8Bladé J,Sonneveld P,San Miguel JF,et al.Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma:efficacy and safety in patients with renal function impairment.Clin Lympgoma Myeloma,2008,8:352-355.
  • 9Greipp PR,San Miguel J,Durie BG,et al.International staging systerm for multiple myeloma.J Clin Oncol,2005,23:3412-3420.
  • 10李娟,赵莹,罗绍凯,黄蓓晖,张国材,彭爱华,郑冬,苏畅,许多荣,童秀珍,谷景立,丁艳.223例新诊断多发性骨髓瘤临床特点及疗效分析[J].中华医学杂志,2008,88(30):2140-2143. 被引量：21

二级参考文献8

  • 1麦玉洁,邱录贵,李睿,靳风艳,白洁,万长春,王建祥,季林祥,肖志坚,钱林生.432例多发性骨髓瘤临床分析[J].白血病．淋巴瘤,2004,13(4):198-201. 被引量：27
  • 2陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量：44
  • 3武永吉.多发性骨髓瘤//张之南,沈悌,血液病诊断及疗效标准,3版.北京:科学出版社,2007:232-235.
  • 4Blade J, SamsonD, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. european group for blood and marrow transplant. Br J Haematol, 1998,102 : 1115-1123.
  • 5Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 2003, 78:21-33.
  • 6Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol, 1994, 12:2398-2404.
  • 7Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol, 1991,47:262-267.
  • 8庄俊玲,武永吉,钟玉萍,何坚,沈悌,张之南.多发性骨髓瘤218例临床分析[J].中国实用内科杂志,2004,24(2):108-110. 被引量：61

共引文献25

同被引文献30

  • 1Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma[J]. Blood Cancer J,2015,5(3)..e296.
  • 2Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma[J]. Clin J Am Soc Nephrol,2013,8 (11) :2007 2017.
  • 3Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoelonal IgG deposits [J]. J Am Soc Nephrol, 2009,20(9) : 2055-2064.
  • 4Findlay M, Isles C. Clinical companion in nephrology[M]. Switzerland : Springer, 2015 : 71-75.
  • 5Findlay M, Isles C. Overview of chronic kidney disease [ M]. Switzerland : Springer, 2015 : 101-106.
  • 6Nasr, SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease : a report of 64 patients from a single institution[J]. Clin J Am Soc Nepbrol, 2012,7(2) :231 239.
  • 7Dimopoulos MA, Terpos E, Chanan Khan A, et al. Renal impairment in patients with multiple myeloma:a consen sus statement on behalf of the International Myeloma Working Group[J]. J Clin Oncoi, 2010, 28 (33) : 4976 4984.
  • 8Sarkozi R, Perco P, Hochegger K, et al. Bortezomib in duced survival signals and genes in human proximal tubu lar cells[J]. J Pharmacol Exp Ther, 2008,327 (3) : 645- 656.
  • 9Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal fail- ure with bortezomib-based regimens[J]. Leukemia Lyre phoma,2008,49(5) :890 895.
  • 10Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment:cohort analysis of the phase m VISTA study[J]. J Clin Oncol, 200{,, 27 (36) :6086 6093.

引证文献2

二级引证文献23

中华血液学杂志
2010年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部